Replies to post #205459 on Biotech Values

[DewDiligence]

EXAS—CEO/COO/CSO sold cumulative $28M of stock during the past week or so:

https://www.sec.gov/Archives/edgar/data/1124140/000120919116150334/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150333/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150335/xslF345X03/doc4.xml

Cologuard is a fine product, but selling a diagnostic for colorectal cancer is a tough way to make money.

EXAS lost $38M in 3Q16 and $130M during 2016’s first nine months. Cologuard was approved by the FDA more than two years ago (#msg-105198793).